BPaLM Regimen

• The Union Health Ministry has approved the introduction of the BPaLM regimen for multidrug-resistant tuberculosis (MDR-TB) treatment in India.
• It consists of four drugs—Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin. It has proven to be a safer, more effective, and quicker option compared to the previous MDR-TB treatments.
• It is part of efforts to eliminate TB by 2025, five years ahead of the global target under the Sustainable Development Goals.
• The BPaLM regimen was incorporated into the National TB Elimination Programme.
• Pretomanid, one of the key drugs, had already been approved by the Central Drugs Standard Control Organisation.

Dig Deeper: Read about XDR TB and missing TB patients in India TB Report 2024.